Apelin Therapy for Restoring Lymphatic Flow in Lymphedema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lymphedema, characterized by lymphatic dysfunction leading to fluid and fat accumulation, inflammation, and fibrosis, lacks effective treatments beyond massages and compressive bandaging, with fibrosis worsening lymphatic vessel obstruction and limb swelling.
Innovation Solution
The use of apelin, a bioactive peptide, to restore lymphatic flow by administering a therapeutically effective amount of apelin polypeptide or a polynucleotide encoding apelin, which stimulates lymphatic pumping and inhibits fibrosis through eNOS-mediated lymphatic pumping and increased lymphatic density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If fibrosis develops in lymphedema, then tissue density increases, but lymphatic vessel obstruction worsens and limb swelling increases
Solution Approach 1:
The patent applies this principle by using apelin, a peptide that naturally inhibits fibrosis formation. By administering apelin, the harmful fibrotic process is converted into a beneficial anti-fibrotic effect, reducing tissue density and preventing lymphatic vessel obstruction while maintaining structural integrity.
Solution Approach 2:
The patent changes the biochemical parameter of tissue composition by introducing apelin, which modifies the fibrotic process. This parameter change transforms the tissue environment from pro-fibrotic to anti-fibrotic, reducing collagen deposition and improving lymphatic vessel patency.
2Object-affected harmful factors
If apelin is administered to treat lymphedema, then limb swelling and fibrosis are reduced, but the mechanism of action is complex involving multiple pathways
Solution Approach 1:
The patent applies this principle by selecting apelin, a peptide that performs multiple functions simultaneously: it inhibits fibrosis, stimulates lymphatic vessel formation, improves lymphatic pumping, and reduces inflammation. This multi-functionality allows a single agent to address multiple aspects of lymphedema pathogenesis, simplifying treatment despite the complexity of individual mechanisms.
Solution Approach 2:
The patent uses apelin as an intermediary substance that mediates between the lymphedema condition and therapeutic outcomes. Apelin acts as a bioactive mediator that translates into multiple beneficial effects through various signaling pathways, including TGF-β inhibition and eNOS activation, thereby reducing limb swelling and fibrosis.
3Speed
If apelin stimulates lymphatic pumping via eNOS, then lymphatic flow improves, but this requires activation of specific signaling pathways
Solution Approach 1:
The patent applies this principle by utilizing the body's own signaling pathways (eNOS/Akt) that are already present in lymphatic endothelial cells. Apelin activates these endogenous pathways, allowing the lymphatic system to self-regulate and improve its pumping function without requiring external intervention in the signaling mechanism itself.
Solution Approach 2:
The patent changes the biochemical state of lymphatic endothelial cells by activating eNOS through apelin binding. This parameter change in signaling pathway activation leads to increased nitric oxide production, which directly improves lymphatic vessel contractility and flow speed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Apelin significantly reduces limb swelling and dermal fibrosis, promoting lymphatic vessel plasticity and contractility, and enhances lymphatic density, offering a novel treatment for lymphedema.
Implementation Method 1
apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells
Implementation Method 2
apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells
Implementation Method 3
apelin decreases renal and skin fibrosis by inhibiting the TGFβ signaling
Implementation Method 4
Apelin stimulates NO production via PI3K/Akt signalling in blood endothelial cells
Implementation Method 5
Apelin stimulates NO production via PI3K/Akt signalling in blood endothential cells
Implementation Method 6
apelin was able to restore the lymphatic shape of precollecting vessels in the infarct area suggesting that apelin may represent a good candidate to restore the lymphatic shape in injured tissues
Data Source
AI summary
Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow in lymphedema. They found a significant decrease in apelin expression in women lymphedematous arm compared to their normal arm. Using an apelin-knockout mouse model, they confirmed the crucial role of apelin as lymphedema was maintained more than 4 weeks after surgery and was associated with a lack of dermis lymphangiogenesis and increased dermal backflow. The inventors show that intradermal injection of apelin-lentivector significantly reduced limb swelling. This was associated with a reduction of dermis fibrosis and increase in lymphatic density. Importantly, apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells (LEC). This was associated with significant increase in E2F8-targeted gene expression through the direct binding of E2F8 on CCBE1 promoter in LEC. Taken together, the results show that apelin plays a key role in lymphedema and thus represents a novel partner for VEGF-C to prevent limb swelling and tissue fibrosis in lymphedema.